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We recently reported de novo GATA6 mutations as the most com-
mon cause of pancreatic agenesis, accounting for 15 of 27 (56%)
patients with insulin-treated neonatal diabetes and exocrine pan-
creatic insufficiency requiring enzyme replacement therapy. We
investigated the role of GATA6 mutations in 171 subjects with neo-
natal diabetes of unknown genetic etiology from a cohort of 795
patients with neonatal diabetes. Mutations in known genes had
been confirmed in 624 patients (including 15 GATA6 mutations).
Sequencing of the remaining 171 patients identified nine new case
subjects (24 of 795, 3%). Pancreatic agenesis was present in 21 case
subjects (six new); two patients had permanent neonatal diabetes
with no enzyme supplementation and one had transient neonatal
diabetes. Four parents with heterozygous GATA6 mutations were
diagnosed with diabetes outside the neonatal period (12–46 years).
Subclinical exocrine insufficiency was demonstrated by low fecal
elastase in three of four diabetic patients who did not receive
enzyme supplementation. One parent with a mosaic mutation
was not diabetic but had a heart malformation. Extrapancreatic
features were observed in all 24 probands and three parents, with
congenital heart defects most frequent (83%). Heterozygous
GATA6 mutations cause a wide spectrum of diabetes manifesta-
tions, ranging from pancreatic agenesis to adult-onset diabetes with
subclinical or no exocrine insufficiency. Diabetes 62:993–997,
2013
Exome sequencing recently led to the discoverythat heterozygous GATA6 mutations are themost common cause of pancreatic agenesis, ac-counting for 15 of 27 patients with neonatal di-
abetes (NDM) requiring insulin treatment and exocrine
pancreatic insufficiency requiring enzyme replacement
therapy (1). This finding supports a previously unrecog-
nized essential function of GATA6 in human pancreatic
development. Extrapancreatic features are common and
include biliary tract defects and gut and other endocrine
abnormalities. Fourteen of the 15 patients had a congenital
cardiac malformation, consistent with previous reports of
GATA6 mutations causing structural heart defects (2–4).
NDM is a rare disorder, with a reported incidence of
1:100,000 (5); a genetic diagnosis is possible in 60–75% of
cases. The transient form (TNDM), which accounts for
;50% of cases, is most frequently due to abnormalities of
the paternally expressed genes on chromosome 6q24 (6).
Mutations in the potassium channel genes KCNJ11 and
ABCC8 and in the INS gene encoding insulin also result in
TNDM and are the most common causes of permanent
neonatal diabetes (PNDM) (7–12).
Mutations in genes encoding transcription factors that
are critical for pancreatic development can cause syn-
dromic NDM. These includeHNF1B (13), GLIS3 (14), RFX6
(15), NEUROD1 (16), and NEUROG3 (17). Each genetic
subtype is characterized by specific extrapancreatic de-
velopmental defects.
Complete absence of the pancreas can result from
biallelic PDX1 or PTF1A mutations (18,19) or from het-
erozygous GATA6 mutations (1). The PDX1 and PTF1A
transcription factors are both expressed early during pan-
creatic development and actively regulate the differentia-
tion of pancreatic precursors toward an endocrine or
exocrine fate (20). Hypomorphic PDX1 mutations have
subsequently been identified in patients with PNDM without
clinical symptoms of exocrine deficiency (21).
In this study, we undertook GATA6mutation screening in
171 subjects with NDM of unknown genetic etiology from
a cohort of 795 patients with NDM and describe the spec-
trum of pancreatic and extrapancreatic phenotypes in 29
case subjects with GATA6 mutations.
RESEARCH DESIGN AND METHODS
Subjects. Patients were selected from an international cohort of 795 case
subjects from 71 countries with diabetes diagnosed before 6 months of age.
Pancreatic agenesis, defined as diabetes needing insulin and pancreatic exo-
crine insufficiency requiring enzyme supplementation therapy, was diagnosed
in 39 of 795 case subjects. We previously studied 27 of these 39 case subjects
with pancreatic agenesis (1). A genetic cause was identified in 624 of the 795
case subjects; these include 15 patients with pancreatic agenesis who are
heterozygous for a GATA6 mutation (1). Mutations in PTF1A and PDX1 were
excluded in all the patients with pancreatic agenesis.
We sequenced GATA6 in the remaining 171 patients in whom no genetic
etiology had been identified. These included 24 case subjects with pancreatic
agenesis (NDM requiring insulin and pancreatic exocrine insufficiency re-
quiring enzyme supplementation therapy). NDM without exocrine insuf-
ficiency was reported in 147 patients: 126 with PNDM and 21 with TNDM.
Mutations in ABCC8, KCNJ11, INS, and chromosome 6q24 abnormalities had
been excluded.
Clinical information was provided by the referring clinicians via a NDM
request form (available at www.diabetesgenes.org) or from clinical notes. The
study was conducted in accordance with the Declaration of Helsinki principles
with informed parental consent given on behalf of children.
Molecular genetic analysis.We screened the coding sequence and;50 bp of
flanking sequence of GATA6 using Sanger sequencing as described previously
(primers) (1). Sequencing reactions were run on an ABI3730 capillary machine
(Applied Biosystems, Warrington, U.K.) and analyzed using Mutation Sur-
veyor v3.98 (SoftGenetics, State College, PA) (GATA6 nucleotide reference
NM_005257.3).
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The bioinformatics tools SIFT, PolyPhen-2, and Align GVGD were used to
predict the effect of novel variants on the GATA6 protein (protein reference
NP_005248.2).
Microsatellite analysis of parent/proband trios using the PowerPlex kit
(Promega, Southampton, U.K.) was used to confirm apparently de novo
mutations. The parental origin of de novo mutations in pedigrees with inherited
mutations was investigated when grandparental samples were available by
analyzing microsatellites D18S1149, D18S1104, D18S1067, D18S1001, D18S869,
and D18S1002.
RESULTS
GATA6 mutations were identified in 9 of 171 probands and
five parents. Six of the probands have pancreatic agenesis.
In total, we have now identified GATA6 mutations in 21 of
39 (54%) patients with pancreatic agenesis (6 case subjects
in this study and 15 reported by Lango Allen et al. [1]).
Three of 147 patients (2%) with NDM but not on exocrine
supplementation were heterozygous for GATA6mutations;
2 have permanent diabetes, and 1 has transient episodes of
hyperglycemia.
GATA6 mutations. The nine novel mutations include
three missense changes (p.C447R, p.G469E, and p.R479G)
and four splicing, one frameshift, and one nonsense mu-
tation. In total, 23 different GATA6 mutations have been
identified in patients with diabetes (p.R456C was present
in two unrelated patients) (Fig. 1). All missense mutations
affect highly conserved residues within the second zinc-
finger domain, which is needed for DNA binding and protein-
protein interaction. None of the mutations were present in
the dbSNP137, 1000 Genomes (March 2012 release, based on
1,197 individuals), or Exome Variants Server (June 2012 re-
lease, based on 6,503 individuals) databases. They were
predicted to affect protein function by at least two of the
bioinformatics predictive tools used (Supplementary Table
1). Three mutations affect conserved splice sites, and in
silico analysis suggested aberrant splicing for the intronic
c.1303–10C.G, c.1516+4A.G, c.1429–8T.G, and c.1429–
41_1441del mutations (see Supplementary Table 2).
Parental DNA samples were available for eight of nine
previously unreported patients. Mutations were shown to
have arisen de novo in three patients and been inherited
from a parent in five case subjects (see Fig. 2). The anal-
ysis of grandparental samples in families ISPAD 207,
ISPAD 208, ISPAD 209, and ISPAD 212 showed that the
mutation had arisen de novo in the parent on the grand-
maternal allele in three case subjects and on the grand-
paternal allele in the remaining one. The level of the
GATA6 mutation in one parent (ISPAD 208-2) was esti-
mated at ;20% in leukocyte DNA.
Diabetes phenotype. The median age at diagnosis of di-
abetes for the 24 probands with GATA6 mutations was 2
days (IQR 1–7 days) and median birth weight was 1,588 g
(SDS = 23.22, ,1st percentile). Pancreatic imaging had
been undertaken in 18 of 21 pancreatic agenesis case
subjects and showed complete absence (n = 8) or marked
hypoplasia (n = 10) of the pancreas. Measurement of fecal
elastase or fecal fat in 15 case subjects showed severe
exocrine pancreatic insufficiency.
The two probands with PNDM but not requiring treat-
ment with pancreatic enzyme supplementation were di-
agnosed at 1 day (c.1303–1G.T) or 1 week (p.C447R) of
age, and both have been treated with insulin since di-
agnosis. Although they had never received enzyme supple-
ments, fecal elastase measurement in ISPAD 208 showed
exocrine insufficiency (,15 mg/g, normal range.200 mg/g).
FIG. 1. Mutations diagram. Genomic and protein positions of the 23 GATA6 mutations. The nine novel mutations are highlighted in bold.
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FIG. 2. Pedigrees. Partial pedigrees of the nine novel case subjects reported. Arrows indicate probands. The genotype is shown underneath each
symbol. N/N denotes no mutation identified. Below the genotype is the type of diabetes (PA, pancreatic agenesis), age of diagnosis, treatment (ER,
enzyme replacement), pancreatic imaging result, and fecal elastase (FE) measurement (N/A, not available). Arrows indicate the proband. Colors
indicate phenotypic features: black, diabetes; red, congenital heart defect; green, hepatobiliary defects; blue, neurocognitive defects; yellow,
hypothyroidism/hypopituitarism; purple, gut malformations.
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The patient with the de novo p.R479G mutation (ISPAD
206) was diagnosed with diabetes at age 8 weeks (glucose
28 mmol/L) and treated with insulin for 1 week during an
enteroviral meningitis infection. During the past 4 years, he
has twice presented with hyperglycemia, during a rotavirus
infection and after surgery to repair his congenital heart
defect. Now 5 years of age, his fecal elastase level is low (61
mg/g, normal range .200 mg/g), but he is not receiving in-
sulin or pancreatic enzyme supplementation treatment.
Five patients had inherited their GATA6 mutation from
a parent (Fig. 2). The parent with a mosaic mutation is not
diabetic at 43 years of age, but the four heterozygotes were
diagnosed with diabetes at 12–46 years of age and treated
with insulin (three case subjects) or metformin. The parent
diagnosed at 12 years of age tested negative for GAD
autoantibodies and is receiving a nonreplacement dose of
insulin (0.35 units/kg/day). Fecal elastase levels were mea-
sured in three parents and showed subclinical exocrine in-
sufficiency (40 mg/g) in one of them (ISPAD 212-02).
Extrapancreatic features. All the patients with NDM
and three of five parents with a GATA6mutation also show
extrapancreatic features (see Table 1 and Fig. 2). Con-
genital heart defects are most common, present in 21 of 24
probands and three parents (83%), and required surgical
correction in 19 case subjects.
Additional extrapancreatic features in the probands in-
clude congenital hypothyroidism (n = 6), hepatobiliary
malformations (in particular gallbladder agenesis and bil-
iary atresia, n = 5), and gut abnormalities (intestinal mal-
rotation and hernias, n = 6). Eleven patients also have
a significant neurocognitive deficit. Three parents had car-
diac malformations, but no other features were reported.
DISCUSSION
This study of a large cohort of patients with NDM confirms
that GATA6 mutations are the major cause of pancreatic
agenesis (1). Familial studies showed that heterozygous
GATA6 mutations can also cause adolescent/adult-onset di-
abetes. Four parents were diagnosed with diabetes at 12–46
years of age and treated with insulin (n = 3) or metformin,
and none had received pancreatic enzyme supplements.
Fecal elastase measurement in two diabetic parents showed
subclinical exocrine insufficiency in one and a normal level
in the other. Our data therefore extend the diabetic pheno-
typic spectrum of GATA6 mutations from pancreatic agen-
esis to adult-onset diabetes without exocrine insufficiency.
This study describes 29 subjects (24 probands and 5
parents) with GATA6 mutations from an international co-
hort of 795 subjects with NDM Within this large cohort,
GATA6mutations account for at least 3% of NDM cases. Of
24 probands with GATA6 mutations, 21 had pancreatic
agenesis, and GATA6 mutations were present in 21 of 39
(54%) patients with pancreatic agenesis. Mutations were
also identified in three patients with NDM who were not
receiving enzyme supplementation; fecal elastase was
measured in two case subjects and showed subclinical
exocrine insufficiency.
The mutation in the four diabetic parents appeared
heterozygous in leukocyte DNA samples, consistent with
a spontaneous mutation in a parental germ cell rather than
a postzygotic mosaic mutation in the developing embryo.
One parent was shown to be a somatic mosaic (suggesting
a postzygotic event) and was not diabetic at 43 years of
age, although she had surgery to correct a patent ductus
arteriosus as a child. Her risk of developing diabetes will
depend on the mutational load in the pancreas.
These data confirm previous evidence of the essential
function of GATA6 in the development of the human
pancreas. In mouse models, GATA6 expression was sig-
nificantly increased during endocrine differentiation (22),
suggesting that it might also be involved in the last stages
of b-cell development. The variation in the pancreatic
phenotype is also seen with heterozygous mutations in
HNF1B, another b-cell transcription factor associated with
early pancreatic development (23).
Consistent with the initial discovery of GATA6 muta-
tions as a rare cause of isolated congenital heart defects
(2–4), cardiac malformations were the most common ex-
trapancreatic feature (83% of case subjects with a GATA6
mutation) in our cohort. Studies in mouse models have
confirmed the role of GATA6 as one of the master regu-
lators of heart formation during embryo development (24).
Our study extends the phenotypic spectrum of GATA6
mutations from isolated congenital heart defects to pan-
creatic agenesis with cardiac malformations and adult-
onset diabetes with/without heart defects.
In addition to congenital heart defects, a wide range of
extrapancreatic malformations were observed in patients
with GATA6 mutations. The most common features were
hypothyroidism, hepatobiliary malformations (mostly gall-
bladder agenesis and biliary atresia), and gut abnormalities
(mostly congenital hernias). All these defects affect organs
of endodermal origin, suggesting a defect in early embry-
onic differentiation. Gata62/2mice die early during embryo
development (embryonic day 6.5–7.5) and show a specific
defect in endodermal differentiation, including severely
downregulated expression of endodermal markers such as
Gata4, Hnf4a, Hnf3b, and Afp (25). Our data suggest a role
for GATA6 in the development of endodermal-derived
organs in humans too.
This study shows that GATA6 mutations cause a vari-
able diabetic phenotype, ranging from pancreatic agenesis
to adult-onset diabetes. Most, but not all, patients have
exocrine insufficiency and other extrapancreatic features.
Further work is needed to establish the prevalence of
GATA6 mutations as a cause of monogenic diabetes pre-
senting outside the neonatal period.
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